Face taping promises smoother skin and fewer wrinkles without injectables, but evidence suggests any visible benefits are largely temporary.
News|Articles|March 27, 2025
Interview Intersection: Expert Interviews From March 2025
Author(s)Emma Andrus, Editor
Dermatology Times is recapping our exclusive expert interviews from the month of March.
Advertisement
Advertisement
Takeda is enhancing diversity in clinical trials through community outreach, investigator training, and AI-driven inclusive medical imagery. LaShell Robinson emphasized efforts to close trust gaps and ensure equitable representation, including partnerships with organizations like the National Psoriasis Foundation.
Related to this article
Castor oil has become a popular social media remedy for thicker, longer hair, but evidence supporting its ability to stimulate hair growth remains limited.
Can “Botox in a bottle” really rival injectable neuromodulators? We examine the evidence behind topical peptide serums and Argireline.
Atopic dermatitis care is evolving with flexible biologic dosing, expanded pediatric options, and novel oral, topical, and systemic therapies.
Updated SKYRIZI labeling allows clinicians to use clinical judgment when determining the need for TB evaluation before treatment.
Experts outline how to recognize undertreated psoriasis, assess incomplete response, and make individualized decisions when escalating therapy.
ATI-052 improved disease severity and itch in a phase 1b trial of patients with severe atopic dermatitis, with no grade 3 or 4 adverse events.
LRM will evaluate injectable rhPDGF-BB as a regenerative approach to infraorbital hollowing in a randomized phase 2b trial.
Advertisement
Advertisement